In vivo  characterization of the highly selective monoacylglycerol lipase inhibitor  KML 29: antinociceptive activity without cannabimimetic side effects | Zendy

IgnatowskaJankowska B M | Zendy; Ghosh S | Zendy; Crowe M S | Zendy; Kinsey S G | Zendy; Niphakis M J | Zendy; Abdullah R A | Zendy; Tao Q | Zendy; O' Neal S T | Zendy; Walentiny D M | Zendy; Wiley J L | Zendy; Cravatt B F | Zendy; Lichtman A H | Zendy

Premium

In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML 29: antinociceptive activity without cannabimimetic side effects

Author(s) -

IgnatowskaJankowska B M,

Ghosh S,

Crowe M S,

Kinsey S G,

Niphakis M J,

Abdullah R A,

Tao Q,

O' Neal S T,

Walentiny D M,

Wiley J L,

Cravatt B F,

Lichtman A H

Publication year - 2014

Publication title -

british journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.432

H-Index - 211

eISSN - 1476-5381

pISSN - 0007-1188

DOI - 10.1111/bph.12298

Subject(s) - monoacylglycerol lipase , anandamide , catalepsy , pharmacology , chemistry , fatty acid amide hydrolase , cannabinoid , endocannabinoid system , cannabinoid receptor , hyperalgesia , allodynia , diacylglycerol lipase , agonist , nociception , receptor , biochemistry , medicine , endocrinology , dopamine , haloperidol

Since monoacylglycerol lipase (MAGL) has been firmly established as the predominant catabolic enzyme of the endocannabinoid 2-arachidonoylglycerol (2-AG), a great need has emerged for the development of highly selective MAGL inhibitors. Here, we tested the in vivo effects of one such compound, KML29 (1,1,1,3,3,3-hexafluoropropan-2-yl 4-(bis(benzo[d][1,3]dioxol-5-yl)(hydroxy)methyl)piperidine-1-carboxylate).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research